Company Overview and News

MPCALA taps Leighton for Cavite segment of CALAX

2018-04-09 bworldonline
MPCALA HOLDINGS, Inc. has tapped Leighton Asia to build the Cavite segment of the Cavite-Laguna Expressway (CALAX).

LinkedIn: Top companies to work for in Australia

2018-03-25 cnbc
International professional services firms and banks dominate the list of the best companies to work for in Australia in 2018, according to LinkedIn's latest ranking.

CIMIC joins BHP, Rio on LinkedIn top companies list

CIMIC Group is the first of several mining and related services companies that have been named in LinkedIn’s 2018 Top Companies list for Australia.

Thiess secures $190m contract extension at Anglo’s Dawson South mine

Anglo American has awarded Thiess a $190 million contract extension to continue providing mining services at the Dawson South metallurgical coal mine in Queensland’s Bowen Basin.

Advice from investors earning 37%

David Koch and the Money Saver HQ team give you the inside scoup on how to invest in shares.

Sedgman wins $40m EPC contract at Century zinc mine

New Century Resources has awarded a $40 million engineering, procurement and construction (EPC) contract to Sedgman for the Century zinc mine restart in Queensland.

Fletcher Building ignored warnings, says shareholders body

The board of Fletcher Building ignored warnings that all was not well at the company, according to the New Zealand Shareholders Association.

Fletcher Building shares hit two-year low after shock downgrade

Fletcher Building's shares tumbled to a two-year low of $6.69 today after the company unveiled further provisions at Building + Interiors (B+I) that bring two-year losses at the unit to $952 million.

CALAEx Laguna Blvd-Mamplasan section to open by December

2018-02-08 bworldonline
THE LAGUNA Boulevard to Mamplasan section of the Cavite-Laguna Expressway (CALAEx) can be opened by December, according to Department of Public Works and Highways (DPWH) Secretary Mark A. Villar.

CIMIC soars on dividend lift, new forecast

CIMIC Group's shares have soared after the construction giant raised its dividend by 13 cents on the back of a 21 per cent lift in full-year profit and forecast a rise in profit in the year ahead.

MPTC to raise P35 billion for 2 projects

2018-01-28 bworldonline
METRO PACIFIC Tollways Corp. (MPTC) plans to raise P35 billion during the first quarter to fund its Cavite-Laguna Expressway (CALAX) and the C-5 South Link project.

MPIC tollways unit allots P10B for south projects

2018-01-07 bworldonline
METRO PACIFIC Tollways Corp. (MPTC) is set to spend P10 billion this year for its projects located in the south of Metro Manila.

QCoal awards $100m of Byerwen contracts to Sedgman

Mineral processing contractor Sedgman has won contracts at QCoal Group’s Byerwen coal mine in Queensland worth almost $100 million.

Dacian Gold lines up Macmahon for $250m Mt Morgans contract

Macmahon Holdings has received a letter of award for a mining contract worth at least $250 million at Dacian Gold’s Mt Morgans gold operation in Western Australia.

Shareholders begin voting against ASX200 directors for having no women on their boards: ACSI

Boards refusing to appoint a woman on their board are being punished by shareholders who are exercising their right to vote against reelection of directors at company annual general meetings.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...